^
over2years
Intratumoural heterogeneity with different resistant subclones in a treatment resistant gastrointestinal stromal tumour revealed through a novel tissue masking technology (ECP 2022)
Background & objectives: A 73-year-old man with a history of metastatic small bowel gastrointestinal stromal tumour (GIST) who have undergone liver and small bowel resections was found to have recurrent peritoneal nodules on follow-up despite being on Imatinib... This case demonstrated the utilization of Quantumcyte Oncomask, a novel tissue masking technology in detection of heterogeneous resistant subclones in a treatment resistant GIST. It enables the sampling of targeted areas in a tumour section to increase the cellular purity for molecular sequencing especially for the analysis of tumour heterogeneity which is known to be associated with therapeutic resistance. The presence of different mutation subclones in GIST is also important in guiding oncologists on the treatment choices.
ANO1 (Anoctamin 1)
|
KIT mutation • KIT exon 11 mutation • KIT N822K • KIT exon 17 mutation • KIT N822Y
|
imatinib